Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
City of Hope Medical Center
University of Arizona
Ascentage Pharma Group Inc.
Dana-Farber Cancer Institute
City of Hope Medical Center
Xencor, Inc.
Barbara Ann Karmanos Cancer Institute
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
University of Wisconsin, Madison
University of Maryland, Baltimore
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
California Cancer Consortium
Massachusetts General Hospital
University of Louisville
Dana-Farber Cancer Institute
Yale University
Alliance for Clinical Trials in Oncology
City of Hope Medical Center
National Cancer Institute (NCI)
Cellerant Therapeutics
Indiana University
Indiana University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Enzon Pharmaceuticals, Inc.
Northwestern University
Northwestern University
National Institutes of Health Clinical Center (CC)
NYU Langone Health
Case Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Arizona
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins